🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,54 USD

Máx. histórico

178,74

2142 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,63%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,20%

Cierre anterior

18,32

Rango de hoy

18,29 – 18,81

Volumen hoy

1.397.929

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,44%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 14 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/02/2000 161,25 163,50 145,50 148,88 -2,93% 11,16% 44.117
11/02/2000 139,50 154,50 139,50 153,38 +11,75% 10,75% 92.967
10/02/2000 160,50 162,00 126,00 137,25 -12,65% 22,43% 162.950
09/02/2000 156,00 162,00 147,00 157,13 +11,44% 9,62% 140.017
08/02/2000 125,63 144,00 121,50 141,00 +18,99% 17,91% 140.583
07/02/2000 113,25 122,25 109,88 118,50 +18,80% 10,93% 134.900
04/02/2000 101,25 109,50 99,00 99,75 +3,91% 10,37% 107.650
03/02/2000 90,00 96,00 89,63 96,00 +11,30% 7,08% 79.767
02/02/2000 84,00 86,25 83,63 86,25 +4,55% 3,13% 43.633
01/02/2000 68,63 84,38 67,50 82,50 +19,57% 24,59% 47.917
31/01/2000 75,38 75,38 61,50 69,00 -14,02% 18,41% 50.333
28/01/2000 90,38 90,38 79,88 80,25 -10,46% 11,62% 47.850
27/01/2000 86,25 93,00 86,25 89,63 +7,17% 7,83% 101.817
26/01/2000 84,19 85,88 81,75 83,63 +0,90% 4,90% 33.083
25/01/2000 86,25 86,63 81,75 82,88 +0,91% 5,65% 47.033
24/01/2000 80,06 85,50 79,88 82,13 +2,34% 7,03% 89.367
21/01/2000 85,50 86,25 75,75 80,25 +0,00% 12,28% 69.433
20/01/2000 78,00 87,00 76,50 80,25 +7,00% 13,46% 139.233
19/01/2000 71,25 84,00 67,13 75,00 +23,84% 23,68% 232.617
18/01/2000 49,50 60,56 49,50 60,56 +29,20% 22,35% 103.167
14/01/2000 47,81 48,00 45,75 46,88 -2,34% 4,71% 22.067
13/01/2000 48,19 50,25 43,88 48,00 +1,59% 13,23% 54.817
12/01/2000 37,50 54,56 37,31 47,25 +28,57% 46,00% 297.550
11/01/2000 35,81 36,75 35,25 36,75 +2,08% 4,19% 22.667
10/01/2000 36,38 37,88 35,25 36,00 +0,00% 7,22% 14.700
07/01/2000 35,81 37,13 35,25 36,00 +5,49% 5,24% 15.417
06/01/2000 33,75 36,00 33,75 34,13 +3,41% 6,67% 22.700
05/01/2000 32,81 33,00 31,88 33,00 +1,15% 3,43% 8.267
04/01/2000 35,25 35,44 31,88 32,63 -5,43% 10,11% 5.083
03/01/2000 32,53 36,00 32,53 34,50 +5,75% 10,66% 15.867